Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 71% Improvement Relative Risk Death/hospitalization 44% Hospitalization 40% c19early.org/pl Dryden-Peterson et al. Paxlovid for COVID-19 EARLY Is early treatment with paxlovid beneficial for COVID-19? Retrospective 44,045 patients in the USA (January - July 2022) Lower mortality (p=0.0064) and death/hosp. (p=0.0001) Dryden-Peterson et al., Annals of Internal Medic.., doi:10.7326/M22-2141 Favors paxlovid Favors control
Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System
Dryden-Peterson et al., Annals of Internal Medicine, doi:10.7326/M22-2141 (date from earlier preprint)
Dryden-Peterson et al., Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System, Annals of Internal Medicine, doi:10.7326/M22-2141 (date from earlier preprint)
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
IPW retrospective 44,551 outpatients age 50+ in the USA, showing lower mortality and hospitalization with paxlovid treatment.
[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 71.0% lower, RR 0.29, p = 0.006, treatment 11,797, control 32,248, propensity score weighting.
risk of death/hospitalization, 44.0% lower, RR 0.56, p < 0.001, treatment 69 of 11,797 (0.6%), control 310 of 32,248 (1.0%), NNT 266, propensity score weighting.
risk of hospitalization, 40.0% lower, RR 0.60, p = 0.001, treatment 11,797, control 32,248, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dryden-Peterson et al., 16 Jun 2022, retrospective, USA, peer-reviewed, 12 authors, study period 1 January, 2022 - 17 July, 2022.
Contact: sldrydenpeterson@bwh.harvard.edu.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.06.14.22276393; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Title: Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system Authors: Scott Dryden-Peterson, MD, MSc Andy Kim, BS Arthur Y. Kim, MD Ellen C. Caniglia, ScD Inga Lennes, MD, MPH, MBA Rajesh Patel, MD, MPH Lindsay Gainer, RN Lisa Dutton, RN Elizabeth Donahue, RN, MSN, NP-C Rajesh T. Gandhi, MD Lindsey R. Baden, MD Ann E. Woolley, MD, MPH Author Affiliations: Brigham and Women’s Hospital, Boston, Massachusetts (Dryden-Peterson, Kim, Baden, Dutton, Donahue, Woolley); Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health (Dryden-Peterson); NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2022.06.14.22276393; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Botswana Harvard AIDS Institute (Dryden-Peterson); Massachusetts General Hospital, Boston, Massachusetts (Kim, Lennes, Gandhi); Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (Caniglia) Mass General Brigham Integrated Care (Gainer); Beth Israel Lahey Health, Cambridge, Massachusetts (Patel) Corresponding Author: Scott Dryden-Peterson, MD, MSc, Division of Infectious Diseases, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. Work: (617) 732-8881. sldrydenpeterson@bwh.harvard.edu Acknowledgement: This work was made possible with help from the Harvard University Center for AIDS Research (CFAR), a funded program of the National Institutes of Health (P30 AI060354) and the National Cancer Institute (R01 CA236546). The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the institutions with which the authors are affiliated. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Drs. Dryden-Peterson and Woolley had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. 2 medRxiv preprint doi: https://doi.org/10.1101/2022.06.14.22276393; this version posted June 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Abstract: Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. Objective: To assess..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit